Development of RGC-Specific Promoters
About the Research Project
Program
Award Type
Standard
Award Amount
$60,000
Active Dates
April 01, 2000 - March 31, 2002
Grant ID
G2000032
Summary
Although a number of factors can cause glaucoma, the loss of vision is ultimately due to the death of the retinal ganglion cells (RGC) of the optic nerve. Changes in cell function, including those that lead to cell death, are reflected in changes in the pattern of genes that are turned on or off in the cell. Dr. Zack is using molecular biological approaches to identify genes that are specifically expressed in the RGC. He will then use the RGC-specific genes to identify the DNA regulatory elements, called promoters, that turn the RGC genes on. The discovery of RGC-specific genes and their promoters would offer valuable resources for further study by the glaucoma research community. The RGC-specific genes could be used to understand molecular events leading to RGC cell death, and the promoters would be useful in attempts to express a variety of genes, including those with potential therapeutic value in retinal ganglion cells.
Related Grants
National Glaucoma Research
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
National Glaucoma Research
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego
Human Retinal Regeneration to Cure Glaucoma
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Karl Wahlin, PhD
Current Organization
University of California, San Diego